Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AVEO Reports Publication Of Positive Tivozanib Phase 2 Results - Quick Facts

RELATED NEWS
Trade AVEO now with 

AVEO Pharmaceuticals Inc. (AVEO: Quote) said the previously reported results from a Phase 2 trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal cell carcinoma were published in the Journal of Clinical Oncology. Results showed improved median progression-free survival or PFS among patients treated with tivozanib compared with placebo, and that tivozanib was well tolerated with minimal off-target toxicities, the company added.

Phase 2 trial's positive results informed the design and implementation of TIVO-1, a pivotal Phase 3 study in advanced RCC demonstrating tivozanib superiority over sorafenib in the primary endpoint of PFS in the first-line setting, top-line data from which were reported in January 2012.

Based on the positive Phase 2 data and success of the TIVO-1 trial, AVEO and its collaborator Astellas Pharma Inc. are moving forward with plans for submitting the tivozanib NDA in RCC in the third quarter of 2012, with the MAA submission to follow.

Click here to receive FREE breaking news email alerts for AVEO Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A number of major retailers will be open on Thanksgiving for early Black Friday shopping events. Kohl's department stores will kick off Black Friday sales two hours earlier this year, at 6 p.m. Thanksgiving Day, while Macy's, Bon-Ton and Best Buy will open at the same time. J.C. Penney and Sears... Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.